Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 31Lung Neoplasms 25Carcinoma, Non-Small-Cell Lung 20Breast Neoplasms 19Lymphoma 18Multiple Myeloma 17Glioblastoma 17Prostatic Neoplasms 16Urinary Bladder Neoplasms 15Glioma 15Carcinoma, Renal Cell 15Melanoma 13Squamous Cell Carcinoma of Head and Neck 12Sarcoma 12Ovarian Neoplasms 12Colorectal Neoplasms 12Central Nervous System Neoplasms 12Triple Negative Breast Neoplasms 11Mouth Neoplasms 11Pancreatic Neoplasms 10Oropharyngeal Neoplasms 10Neuroblastoma 10Medulloblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 10Laryngeal Neoplasms 10Carcinoma, Transitional Cell 10Thyroid Neoplasms 9Fallopian Tube Neoplasms 9Ependymoma 9

Interventions

cixutumumab 2cabozantinib 2Trastuzumab 2Specimen Handling 2Radiotherapy 2Mitotane 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Cisplatin 2tipifarnib 1sodium thiosulfate 1gossypol acetic acid 1entinostat 1cemiplimab 1Vincristine 1Tamoxifen 1Ritonavir 1Oxaliplatin 1Nivolumab 1Microscopy, Electron 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Floxuridine 1Etoposide 1Dichlorodiphenyldichloroethane 1Dexamethasone 1Cytoreduction Surgical Procedures 1CYT-6091 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Adrenocortical Carcinoma × Magnetic Resonance Spectroscopy × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT06900595 2026-05-22

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
48 enrolled
Endocrine

Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡